Table 1.
Clinicopathologic features and expression of TFPI-2
| TFPI-2 negative No.(%) | TFPI-2 positive N0.(%) | χ2 | P value | |
|---|---|---|---|---|
| Age |
|
|
|
|
| ≤55 |
24(68.6%) |
74(61.2%) |
0.639 |
0.424 |
| >55 |
11(31.4%) |
47(38.8%) |
|
|
| Tumor size |
|
|
|
|
| ≤2 cm |
12(34.3%) |
56(46.3%) |
1.589 |
0.208 |
| >2 cm |
23(65.7%) |
65(53.7%) |
|
|
| Skin involvementa |
|
|
|
|
| No |
30(85.7%) |
96(79.3%) |
0.710 |
0.399 |
| Yes |
5(14.3%) |
25(20.7%) |
|
|
| LN metastasis |
|
|
|
|
| No |
9(26.5%) |
70(58.3%) |
10.766 |
0.001 |
| Yes |
25(73.5%) |
50(41.7%) |
|
|
| Unknown |
1 |
1 |
|
|
| Histologic grade |
|
|
|
|
| ≤II |
13(37.1%) |
71(58.7%) |
5.066 |
0.024 |
| >II |
22(62.9%) |
50(41.3%) |
|
|
| Vessel invasion |
|
|
|
|
| Absence |
12(35.3%) |
109(90.0%) |
46.528 |
0.001 |
| Presence |
22(64.7%) |
12(10.0%) |
|
|
| Unknown |
1 |
0 |
|
|
| Clinical stage |
|
|
|
|
| I |
5(14.3%) |
35(28.9%) |
4.809 |
0.090 |
| II |
22(62.9%) |
52(43.0%) |
|
|
| III |
8(22.9%) |
34(28.1%) |
|
|
| ER |
|
|
|
|
| (-) |
12(35.3%) |
43(35.8%) |
0.003 |
0.954 |
| (+) |
22(64.7%) |
77(64.2%) |
|
|
| Unknown |
1 |
1 |
|
|
| PR |
|
|
|
|
| (-) |
15(44.1%) |
63(52.5%) |
0.745 |
0.388 |
| (+) |
19(55.9%) |
57(47.5%) |
|
|
| Unknown |
1 |
1 |
|
|
| HER-2 |
|
|
|
|
| (-) |
17(50.0%) |
62(53.0%) |
0.095 |
0.759 |
| (+) |
17(50.0%) |
55(47.0%) |
|
|
| Unknown |
1 |
4 |
|
|
| Tumor type |
|
|
|
|
| IDCb |
29(82.9%) |
98(81.0%) |
0.062 |
0.803 |
| Non-IDCc | 6(17.1%) | 23(19.0%) |
a skin involvement include: edema, redness, nodularity, or ulceration of the skin.
b IDC, invasive ductal carcinoma.
c Non-IDC include: invasive lobular carcinoma, mucinous or colloid carcinoma, medullary carcinoma, metaplastic carcinoma.